What It Means
- The Kojiesan recall covers batch 039KCTH24G10 of the Skin Lightening Cleanser and Toner with Hydromoist, pulled after FDA testing found hydroquinone, a banned skin lightening ingredient.
- The product carried valid FDA notification before the recall, which means registration status did not prevent a banned ingredient from reaching retail shelves.
- FDA has directed regional field offices, local government units, and law enforcement agencies to pull the affected batch now, not on a fixed future date.
- Retailers and resellers who treat FDA notification as a one time clearance have no built in defense against a recall triggered after approval.
- Marketplace platforms hosting third party cosmetic sellers carry a verification gap between checking registration status and monitoring live regulatory advisories.
The Kojiesan recall of its Skin Lightening Cleanser and Toner with Hydromoist is not really about the brand. It is about what happened after the product cleared FDA notification. A later batch tested positive for hydroquinone, an ingredient banned under the ASEAN Cosmetic Directive, and the paperwork that was supposed to catch that never did. FDA Advisory No. 2026-0699, issued July 2, 2026, was not triggered by a consumer complaint. It came from the FDA’s own post market surveillance testing, which means the failure surfaced after approval, not before it.
Registration Was Never the Finish Line
Every cosmetic sold in the Philippines needs a Certificate of Product Notification before it reaches a shelf. That process checks formulation, labeling, and manufacturer documentation at a single point in time. It does not follow the product after approval. Kojiesan’s cleanser and toner had that notification, and the Kojiesan recall happened anyway, because FDA’s surveillance program tested a batch already in circulation and found hydroquinone in it, a substance the notified formulation was never supposed to contain.
The Kojiesan recall tells compliance teams and retailers something the registration process itself cannot: that a CPN or CPR is a floor, not a guarantee, and batch consistency is the part of the system nobody outside the manufacturer is actively watching.
The Recall Mechanism Nobody Was Watching
FDA’s advisory names the specific lot: 039KCTH24G10, held by BEVi Beauty Elements Ventures, Inc. Hydroquinone exposure carries real risk. FDA lists skin, eye, and respiratory irritation, hypersensitivity reactions, exogenous ochronosis, and potential carcinogenic and genotoxic effects. This is not a labeling technicality. It is a banned ingredient with documented health consequences, found in a product that had already passed the checkpoint the Kojiesan recall was supposed to make unnecessary.
The enforcement directive is immediate. FDA regional field offices, regulatory enforcement units, local government units, and law enforcement agencies are instructed to keep the affected stock out of their jurisdictions. That is not a warning letter. It is a recall with distribution level enforcement attached to it, which puts pressure on the supply chain now, not after a grace period.
Retailers Carry a Risk They Cannot See
The Kojiesan recall exposes a gap most retailers never had to think about. Provincial drugstores, beauty supply resellers, and small distributors typically verify a product once, at intake, by checking whether it carries FDA notification. Few of them track batch or lot numbers at the shelf level. That means a store that stocked Kojiesan in good faith has no easy way to know whether the units on its shelf belong to the recalled lot or a clean one.
This is the part of compliance that registration never solved. A retailer can be fully compliant on paper, carrying a properly notified product, and still be sitting on contaminated stock because the failure the Kojiesan recall exposed occurred downstream of the checkpoint they relied on.
Marketplaces Inherit a Compliance Gap They Did Not Build
Online sellers face the same exposure with less oversight. A marketplace listing a registered cosmetic product usually stops verification at the CPN or CPR stage, the same way a physical retailer does. Few marketplace compliance systems are built to flag a product the moment FDA issues a new advisory against it, which means a live recall and an active listing can coexist for days before anyone catches the overlap.
That gap sits next to a compliance structure HemosPH has already tracked on the platform side. The DTI online marketplace rules push platforms toward tighter merchant verification and faster listing removal under the Internet Transactions Act. The Kojiesan recall adds a second layer platforms were not built around. Registration checks catch unnotified products. They do not catch notified products that failed after the fact, which is exactly what this recall demonstrates.
The Kojiesan Recall Is Not an Isolated Case
Kojiesan is one data point inside a pattern. FDA’s cosmetic advisories category has carried a steady run of warnings this year against unauthorized perfumes and unnotified whitening products sold through informal and online channels. In January, FDA and the Department of Health jointly warned the public against unregistered and counterfeit health products, including cosmetics, sold outside verified channels. The Kojiesan recall on a registered brand is a sharper version of the same underlying problem: the market is producing compliance failures faster than the verification habits retailers and platforms currently use can catch them.
Retailers who still equate FDA notification with permanent safety are working from an outdated model. The batch that failed this time was registered. The next one that fails will likely be too.
Track more regulatory shifts that affect your business in Policy & Regulation section of Hemos PH.
